Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc.

TNDMยทNASDAQ

$19.12

+2.8%
HealthcareMedical - Devices

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

At a Glance

Live Snapshot
Market Cap$1.31B
EPS-3.0400
P/E Ratio-6.29
Earnings Date08/05/2026
3Y-119.0%
5Y-139.0%
10Y-84.0%
3Y+120.0%
5Y-125.0%
10Y+598.0%
3Y-357.0%
5Y-114.0%
10Y-183.0%
TNDM

Tandem Diabetes Care, Inc. Cash Conversion Engine

TNDM ยท NASDAQ
Net Income-204.71M
Depreciation & Amortization13.84M
Stock-Based Compensation92.38M
Change in Working Capital-23.04M
Others111.81M
Capital Expenditures-19.95M
Free Cash Flow-29.67M

Cash Flow Quality Analysis

FCF Conversion Rate

14.5%

Weak cash conversion. Significant portion of earnings not converting to cashโ€”review working capital trends and capital intensity.

CapEx Intensity

-205.2%

Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.

FCF Growth Trend

-694.1%

Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.

Working Capital Impact

-$23.04M

Significant working capital drain. Growth may be consuming cash through inventory buildup or receivables extensionโ€”monitor closely.

Cash Flow Quality Insight

Deteriorating cash generation: Both declining FCF and weak conversion rate signal fundamental challenges. Investigate margin pressure, rising costs, or working capital issues.

Tandem Diabetes Care, Inc. Cash Flow Statement

TNDM โ€ข NASDAQ

Tandem Diabetes Care, Inc. Cash Flow StatementDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015Dec 2014Dec 2013Dec 2012Dec 2011
OPERATING ACTIVITIES
-204.7M
-96M
-222.6M
-94.6M
15.6M
-34.4M
-24.8M
-122.6M
-73M
-83.4M
-72.4M
-79.5M
-63.1M
-33M
-25.5M
13.8M
16.6M
15.7M
14.3M
13.8M
10.5M
6.1M
5.8M
6.9M
5.5M
4.8M
4.4M
3.2M
2M
1.3M
0.0
0.0
0.0
0.0
0.0
-2.1M
15.2M
0.0
-187K
3.9M
478K
298K
10.7M
-1.3M
928.3K
92.4M
101.4M
88.1M
84.9M
60.8M
58.4M
58.1M
23.7M
12.6M
11.7M
13.1M
15M
4.5M
245.8K
253.4K
111.8M
14M
104.7M
50.5M
6.8M
28.9M
-321K
76.3M
3.7M
1.1M
215K
260K
25K
1.1M
544K
(0.0)
(0.0)
(1.9M)
(0.0)
(260K)
(177K)
(67K)
(16K)
(22K)
(23K)
(9K)
(71K)
(19K)
(3K)
(0.0)
-23M
-11.8M
-17.7M
-4.6M
14.4M
-36.6M
-12.3M
8.5M
-16.1M
112K
-5M
-1.8M
-3M
-2.5M
960.8K
-9.7M
24.2M
-31.8M
50.5M
111.4M
24.7M
41.9M
-8.3M
-66.1M
-61.2M
-58.8M
-61.4M
-47.8M
-33.5M
-21.5M
INVESTING ACTIVITIES
-19.9M
-19.2M
-26.8M
-34.1M
-14.2M
-27.4M
-19.5M
-3M
-5.7M
-8.9M
-5.8M
-4.6M
-6M
-5.5M
-1.3M
(0.0)
(0.0)
-69.5M
-25.7M
(0.0)
(0.0)
(37.4M)
(1.7M)
(0.0)
-10.5M
(74K)
(173K)
(0.0)
(0.0)
(0.0)
-85.7M
-264.3M
-535.7M
-467.7M
-733.4M
-497.1M
-164.6M
-123.6M
(0.0)
-30.6M
-80.2M
-67.1M
-5.1M
(0.0)
(0.0)
257.1M
306.5M
546.2M
569.5M
570M
233.3M
127.2M
35.8M
8.5M
50M
88.5M
36.2M
0.0
0.0
7.2M
-78.6M
-46.4M
0.0
-8.9M
-9.3M
-4.9M
-37.4M
-1.7M
8.5M
10.5M
-74K
-173K
-7.1M
-1M
0.0
(72.9M)
-23.5M
-85.7M
(33.2M)
-186.9M
-296.1M
-57M
-90.7M
(2.8M)
(10.4M)
(2.4M)
-35.5M
-11.1M
-5.5M
(5.9M)
FINANCING ACTIVITIES
-2.6M
-36.7M
0.0
17.6M
0.0
0.0
0.0
172.9M
39.8M
0.0
68.3M
3.7M
127.6M
35K
215.3K
-40.8M
44.9M
0.0
0.0
0.0
278.7M
0.0
-87.7M
0.0
50M
0.0
-75K
24.5M
16.6M
13M
(0.0)
-30M
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
0.0
183K
4.1M
-675K
51.9M
35.7M
24.2M
32M
-8M
2.3M
0.0
3.7M
-2M
0.0
0.0
-43.4M
8.4M
4.1M
16.9M
51.9M
314.4M
24.2M
117.2M
32.4M
52.3M
68.3M
3.6M
166.1M
47.5M
13.2M
CASH FLOW SUMMARY
1.6M
1.3M
-212K
827K
153K
387K
191K
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
21.4M
10.4M
-113.6M
101.3M
-23.4M
43.4M
9.3M
18.1M
-31M
1.6M
11.9M
-93.2M
107.2M
8.5M
-2.5M
69.2M
58.9M
172.5M
71.2M
94.6M
51.2M
41.8M
23.7M
44.7M
43.1M
31.2M
124.4M
17.2M
8.7M
11.1M
90.6M
69.2M
58.9M
172.5M
71.2M
94.6M
51.2M
41.8M
13.7M
44.7M
43.1M
31.2M
124.4M
17.2M
8.7M
-29.7M
5M
-58.6M
16.4M
87.8M
-7.6M
22.4M
-11.3M
-71.9M
-70.1M
-64.6M
-66M
-53.8M
-39M
-22.9M

SEC Filings

TNDM - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
8-K

8-K 2026

N/A

May 21, 2026
May 20, 2026
2026
8-K

8-K 2026

N/A

May 15, 2026
May 11, 2026
2026
10-Q

10-Q 2026 Q1

Q1

May 07, 2026
March 31, 2026
2026
8-K

8-K 2026

N/A

May 07, 2026
May 07, 2026
2026
DEF 14A

DEF 14A 2025

N/A

April 07, 2026
December 31, 2025
2025
8-K

8-K 2026

N/A

February 27, 2026
February 23, 2026
2026
10-K

10-K 2025 FY

FY

February 19, 2026
December 31, 2025
2025
8-K

8-K 2026

N/A

February 19, 2026
February 19, 2026
2026
8-K

8-K 2025

N/A

December 30, 2025
December 26, 2025
2025
8-K

8-K 2025

N/A

November 12, 2025
November 07, 2025
2025
Showing 1 to 10 of 237 filings